Case report

Clinically amyopathic dermatomyositis with interstitial lung disease double-positive for anti-MDA5 and anti-PL12 antibodies

Toshiya Hiramatsu a,*, Moeko Murano a, Shogo Nakai a, Yurina Murakami a, Koji Nishimoto a, Sayomi Matsushima a, Masanori Harada a, Tomohiro Uto a, Jun Sato a, Shiro Imokawa a, Takafumi Suda b

a Division of Respiratory Medicine, Iwata City Hospital, 512-3 Okubo, Iwata, Shizuoka, 438-8550, Japan
b Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, 431-3192, Japan

ARTICLE INFO

Keywords: Myositis-specific antibodies Myositis-associated antibodies Chest computed tomography Anti-aminoacyl-tRNA synthetase

ABSTRACT

Anti-melanoma differentiation-associated gene 5 (MDA5) and anti-aminoacyl-tRNA synthetase (ARS) antibodies are two major myositis-specific autoantibodies with distinct clinical features. However, the clinical course remains unclear in patients with clinically amyopathic dermatomyositis (CADM)-interstitial lung disease (ILD) who have co-existing anti-MDA5 and anti-ARS antibodies. Here, we describe the case of a 32-year-old woman with CADM-ILD who had anti-MDA5 and anti-PL12 antibodies. Her serum ferritin level was within the normal range. However, chest computed tomography revealed bilateral lower-lobe consolidation and ground-glass opacities. Treatment with prednisolone and immunosuppressants was successful in improving the skin lesion and ILD, but relapse occurred on reducing the dose of prednisolone. These clinical features match those of anti-ARS antibody-positive dermatomyositis-ILD. Because these two conditions show significantly different clinical features and require different intensities of treatment, clinicians should carefully follow-up these patients throughout the course of the disease.

1. Introduction

Anti-aminoacyl-tRNA synthetase (ARS) and anti-melanoma differentiation-associated gene 5 (MDA5) antibodies are myositis-specific autoantibodies (MSAs) [1,2]. These antibodies tend to differ in their pathophysiological profiles and clinical presentations [3–8]. The coexistence of these MSAs is very rare, and only a few such cases have been reported [9–11]. Here, we describe a rare case of clinically amyopathic dermatomyositis (CADM) associated with interstitial lung disease (ILD) with coexisting anti-PL12 and anti-MDA5 antibodies.

2. Case report

A 32-year-old woman presented to our hospital with a 3-week history of skin rashes. She had arthralgia and low-grade fever over the previous 2 weeks, and complained of dyspnea on exertion at the initial visit. Fine crackles were audible on auscultation bilaterally. She had Gottron papules in her fingers and elbows (Fig. 1a and b), palmar papules (Fig. 1c) and mechanics hands (Fig. 1d), but she had...
never experienced Raynaud’s phenomenon. Neither a heliotrope rash nor a shawl sign was observed. Moreover, she had no muscle pain or weakness.

Laboratory tests yielded the following values: white blood cells, 4600/mL; C-reactive protein, 1.25 mg/dL (normal range: 0.00–0.14 mg/dL); creatine kinase (CK), 274 U/L (normal range: 41–153 U/L); lactate dehydrogenase, 276 U/L (normal range: 124–222 U/L); aldolase, 5.5 U/L (normal range: 2.1–6.1 U/L); ferritin, 50 ng/mL (normal range: 10–60 ng/mL). KL-6 and SP-D levels were also within the normal ranges. The patient also tested positive for rheumatoid factor (RF) and anti-cyclic citrullinated peptide (CCP) antibodies (70 IU/m and 25.6 U/mL, respectively). Anti-ARS and anti-MDA-5 antibodies were detected using an enzyme-linked immunosorbent assay. By using an immunoblot assay, the tRNA component was identified as PL12; anti-Ro52 antibody was also detected. A partial pressure of oxygen was 81.9 mmHg under ambient air by arterial blood gas analysis.

The pulmonary function test showed a slightly restrictive pattern. The results showed that forced vital capacity was 2.23 L (75.1% predicted) and diffusing capacity of the lung for carbon monoxide (DLco) was 19.25 mL/min/mm Hg (101.3% predicted). Chest computed tomography (CT) revealed bilateral consolidation and ground-glass opacification with interlobular septal thickening mainly with bilateral lower-lobe predominance (Fig. 2). The bronchoalveolar lavage fluid was negative for malignant cells and pathogenic organisms, with a total cell count of 0.93 × 10^5 cells/mL and 68.2% alveolar macrophages, 26.8% lymphocytes and 0.6% neutrophils; the ratio of CD4 to CD8 T lymphocytes was 0.87. Transbronchial lung biopsy (right B8a and B3a) showed lymphocyte infiltration and thickening of the alveolar walls without any vasculitis, granulomas, or necrosis (Fig. 3). Skin biopsy showed keratinization of the epidermis and perivascular inflammatory cell infiltration (Fig. 4).

Accordingly, we diagnosed her as having CADM associated with ILD based on Sontheimer’s criteria [12] (Table 1). Treatment with prednisolone (45 mg/day; 1 mg/kg/day) and tacrolimus (3 mg) was started. This improved the skin lesions and ILD (Fig. 5a). However, after gradually reducing the prednisolone dose to 15 mg/day for five months while continuing tacrolimus, she experienced dyspnea on exertion and the chest CT findings worsened (Fig. 5b). Her oxygen saturation by pulse oximetry was 95% under ambient air. The results of %DLco at one month, three months and five months after the starting of initial therapy were 101%, 87.4% and 69.0%, respectively. Therefore, intravenous cyclophosphamide (700 mg every 4 weeks) was added to the regimen. Her respiratory condition stabilized, and chest CT showed no remarkable deterioration.

3. Discussion

The clinical features of MSAs usually differ from one another. Among the MSAs, anti-MDA5 antibody is usually detected in patients with CADM [4,13], which is a subtype of DM with typical skin manifestations but amyopathy or hypomyopathy due to scarce muscle
Inflammation [12, 13]. In our case, hallmark cutaneous manifestations were observed with no clinical evidence of proximal muscle weakness, but the serum CK level was slightly elevated. Therefore, we diagnosed her as having CADM (strictly, hypomyopathic DM) on the basis of Sontheimer’s criteria [12].

Patients with CADM and anti-MDA5 antibody frequently develop complications of rapidly progressive-ILD, with fatal outcomes within the first 6 months, despite adequate treatment with high-dose steroids and immunosuppressants [3-5]. Therefore, anti-MDA5 antibody is considered a useful indicator for the early diagnosis of fatal and rapidly progressive ILD [4,5,14,15]. In contrast, in patients with DM-ILD and anti-ARS antibody, ILD usually responds to steroid treatment but relapse over the years [3,8]. Although our patient tested positive for anti-MDA5, treatment with steroids in combination with immunosuppressants was effective in inducing the remission of ILD. However, she later experienced ILD-flare-up when the steroid dose was reduced. These clinical features appear to match those of anti-ARS antibody-positive DM-ILD.
Previous studies have identified several risk factors, including anti-MDA5 antibodies, chest CT findings of lower-lobe consolidation, and high ferritin levels, that are potentially associated with a poor prognosis in patients with DM-ILD [14–19]. In anti-MDA5-positive patients with DM-ILD, the P/F ratio, alveolar-arterial oxygen gradient, and elevation of aspartate transaminase and gamma glutamyl transeptidase are also associated with poor outcomes [14,16,17]. In our patient, chest CT findings showed lower-lobe consolidations, but the serum ferritin level, P/F ratio, and alveolar-arterial oxygen gradient were within the normal ranges.

A subset of patients with DM has circulating myositis-associated autoantibodies (MAAs) that are often found in other connective tissue diseases [20,21]. Our patient showed RF, anti-CCP, and anti-Ro52 antibodies, which are MAAs. Yamaguchi et al. reported that the coexistence of MAAs could be a biomarker for a favorable prognosis in anti-MDA5- positive patients with CADM; thus, anti-MDA5...
antibodies themselves may not be strong predictors of worse outcomes [21]. Our case findings may support this hypothesis.

In fatal cases of rapidly progressive anti-MDA5-positive DM/CADM-ILD, systemic activation of macrophages is potentially related to the pathogenesis [22, 23]. However, the pathogenesis and clinical features of double-positive MSAs in DM-ILD are unclear because of the rarity of this condition. To date, only four cases of DM/CADM-ILD with anti-ARS and anti-MDA5 antibody double-positive, including our case [9–11], have been reported (Table 2). MAAs were detected in two patients. Three patients responded to treatment with steroids and immunosuppressants, but recurrence occurred [10]. Moreover, all patients were Asian. Anti-ARS antibody was negative when acute exacerbation of ILD occurred in one patient [10]. This case may indicate that macrophage activation is reduced or blocked by some mechanisms in some certain patients with anti-MDA5 antibody-positive DM/CADM-ILD together with anti-ARS antibody. In contrast, another Hispanic patient died of acute respiratory failure due to DM-ILD [11]. Therefore, whether the clinical course presents as ARS-ILD, MDA5-ILD, or their combination remains unclear. The degree of macrophage activation, ethnic factors, or the type of anti-ARS antibody may contribute to the clinical course. Further investigation is warranted to clarify this. (1090 words).

**Authors’ contributions**

TH, MM, SN, YM, KN, SM, MH, TU, JS, and SI contributed to the decision of treatment, collecting clinical data, data analysis, and writing the manuscript. TH, MM, SN, YM, KN, SM, MH, TU, JS, SI and TS contributed to the discussion about the patient. All authors read and approved the final manuscript.

**Support**

The authors received no financial or other material support for the study described in this manuscript.

**Acknowledgement**

All authors thank Dr. Yusuke Sano (Department of Dermatology, Iwata City Hospital) for patient’s management of skin lesion. We would like to thank Editage ([www.editage.com](http://www.editage.com)) for English language editing.

**References**

[1] H. Hozumi, T. Fujisawa, R. Nakashima, T. Johkoh, H. Sumikawa, A. Murakami, N. Enomoto, N. Inui, Y. Nakamura, Y. Hosono, Y. Imura, T. Mimori, T. Suda, Comprehensive assessment of myositis-specific autoantibodies in polymyositis/dermatomyositis-associated interstitial lung disease, Respir. Med. 121 (2016) 91–99.

[2] H. Gunawardena, Z.E. Betteridge, N.J. McHugh, Myositis-specific autoantibodies: their clinical and pathogenic significance in disease expression, Rheumatology 48 (2009) 607–612.

[3] K. Isoda, T. Kotani, T. Takeuchi, T. Kiboshi, K. Hata, T. Ishida, K. Otani, T. Kamimori, H. Fujiwara, T. Shoda, S. Makino, Comparison of long-term prognosis and relapse of dermatomyositis complicated with interstitial pneumonia according to autoantibodies: anti-aminocyl tRNA synthetase antibodies versus anti-melanoma differentiation-associated gene5 antibody, Rheumatol. Int. 37 (2017) 1335–1340.

[4] S. Sato, M. Hirakata, M. Kuwana, A. Suwa, S. Inada, T. Mimori, T. Nishikawa, C.V. Oddis, Y. Ikeda, Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis, Arthritis Rheum. 52 (2005) 1571–1576.

[5] Z. Chen, M. Cao, M.N. Plana, J. Liang, H. Cai, M. Kuwana, L. Sun, Utility of anti-melanoma differentiation-associated gene5 antibody measurement in identifying patients with dermatomyositis and a high risk for developing rapidly progressive interstitial lung disease: a review of the literature and a meta-analysis, Arthritis Care Res. 65 (2013) 1316–1324.
[6] Y. Hamaguchi, M. Fujimoto, T. Matsuhashi, K. Kaji, K. Komura, M. Hasegawa, M. Kodera, E. Muroi, K. Fujikawa, M. Seishima, H. Yamada, R. Yamada, S. Sato, K. Takehara, M. Kuwana, Common and distinct clinical features in adult patients with anti-aminoacyl-tRNA synthetase antibodies: heterogeneity within the syndrome, PLoS One 8 (2013), e60442.

[7] I. Pinal-Fernandez, M. Casal-Dominguez, J.A. Huapaya, J. Albayda, J.I. Paik, C. Johnson, I. Silhan, L. Christopher-Stine, A.L. Mammen, S.K. Danoff, A longitudinal cohort study of the anti-synthetase syndrome: increased severity of interstitial lung disease in black patients and patients with anti-PL7 and anti-PL12 autoantibodies, Rheumatology 56 (2017) 999–1007.

[8] H. Yoshifuji, T. Fujii, S. Kobayashi, Y. Imura, Y. Fujita, D. Kawai, T. Usui, M. Tanaka, S. Nagai, H. Umehara, T. Mimori, Anti-aminoacyl-tRNA synthetase antibodies in clinical course prediction of interstitial lung disease complicated with idiopathic inflammatory myopathies, Autoimmunity 39 (2006) 233–241.

[9] T. Naniwa, S. Tamechika, Y. Okazaki, S. Maeda, M. Kuwana, Coexistence of anti-melanoma differentiation-associated gene 5 and anti-aminoacyl-transfer RNA synthetase antibodies in a patient with dermatomyositis and rapidly progressive and relapsing interstitial lung disease, Med. Rheumatol. Case Rep. 1 (2017) 3–8.

[10] Y. Takeuchi, M. Hashimoto, R. Nakashima, M. Tanaka, N. Kuramoto, K. Murakami, H. Yoshifuji, K. Ohmura, T. Mimori, Anti-EJ, anti-MDA5 double-positive chronic clinically amyopathic dermatomyositis: a case report, Rheumatol. Adv. Pract. (2018), https://doi.org/10.1093/rap/rky022, 2rky022.

[11] Z.Y. Li, E. Gill, F. Mo, C. Reyes, Double anti-PL-7 and anti-MDA-5 positive amyopathic dermatomyositis with rapidly progressive interstitial lung disease in a Hispanic patient, BMC Pulm. Med. 20 (2020) 220, https://doi.org/10.1186/s12890-020-01256-x.

[12] R.D. Sontheimer, Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis sine myositis) as a distinctive subset within the idiopathic inflammatory dermatomyositis spectrum of clinical illness? J. Am. Acad. Dermatol. 46 (2002) 626–636.

[13] S. Sato, M. Kuwana, Clinically amyopathic dermatomyositis, Curr. Opin. Rheumatol. 22 (2010) 639–643.

[14] T. Gono, Y. Kawaguchi, T. Satoh, M. Kuwana, Y. Katsumata, K. Takagi, I. Masuda, A. Tochimoto, S. Baba, Y. Okamoto, Y. Ota, H. Yamanaka, Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis, Rheumatology 49 (2010) 1713–1719.

[15] S. Meghdam-Kia, C.V. Odds, S. Sato, M. Kuwana, R. Aggarwal, Anti-melanoma differentiation-associated gene 5 is associated with rapidly progressive lung disease and poor survival in US patients with amyopathic and myopathic dermatomyositis, Arthritis Care Res. 68 (2016) 689–694.

[16] T. Gono, Y. Kawaguchi, M. Hara, I. Masuda, Y. Katsumata, M. Shinozaki, Y. Ota, E. Ozeki, H. Yamanaka, Increased ferritin predicts development and severity of acute interstitial lung disease as a complication of dermatomyositis, Rheumatology 49 (2010) 1354–1360.

[17] T. Gono, S. Sato, Y. Kawaguchi, M. Kuwana, M. Hanaoka, Y. Katsumata, K. Takagi, S. Baba, Y. Okamoto, Y. Ota, H. Yamanaka, Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis, Rheumatology 51 (2012) 1563–1570.

[18] K. Tanizawa, T. Handa, R. Nakashima, T. Kubo, Y. Hosono, K. Watanabe, K. Aihara, T. Oga, K. Chin, S. Nagai, T. Mimori, M. Mishima, HRCT features of interstitial lung disease in dermatomyositis with anti-CADM-140 antibody, Respir. Med. 105 (2011) 1380–1387.

[19] T. Gono, K. Miyake, Y. Kawaguchi, H. Kaneko, M. Shinozaki, H. Yamanaka, Hyperferritinaemia and macrophage activation in a patient with interstitial lung disease with clinically amyopathic DM, Rheumatology 51 (2012) 1336–1338.

[20] A. Ghirardello, E. Borella, M. Beggio, F. Franceschini, M. Fredi, A. Doria, Myositis autoantibodies and clinical phenotypes, Autoimmun. Highlights 5 (2014) 69–75.

[21] K. Yamaguchi, A. Yamaguchi, C. Kashiwagi, Y. Sawada, K. Taguchi, K. Umetsu, K. Oshima, M. Uchida, M. Suzuki, S. Kono, M. Takemura, H. Masubuchi, S. Kitahara, K. Hara, T. Maeno, S.I. Motegi, Y. Muro, T. Sakairi, T. Hisada, M. Kurabayashi, Differential clinical features of patients with clinically amyopathic dermatomyositis who have circulating anti-MDA5 autoantibodies with or without myositis-associated autoantibodies, Respir. Med. 140 (2018) 1–5.

[22] Y. Horiike, Y. Suzuki, T. Fujisawa, H. Yasui, M. Karayama, H. Hozumi, K. Furuhashi, N. Enomoto, Y. Nakamura, N. Inui, N. Ogawa, T. Suda, Successful classification of macrophage-mannose receptor CD206 in severity of anti-MDA5 antibody positive dermatomyositis associated ILD, Rheumatology 58 (2019) 2143–2152.

[23] T. Fujisawa, H. Hozumi, H. Yasui, Y. Suzuki, M. Karayama, K. Furuhashi, N. Enomoto, Y. Nakamura, N. Inui, T. Suda, Clinical significance of serum chiotritiosidase level in anti-MDA5 antibody-positive dermatomyositis-associated interstitial lung disease, J. Rheumatol. 46 (2019) 935–942.